AstraZeneca entered a strategic discovery and licensing collaboration with insitro to identify causal disease biology and advance therapeutics in metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Insitro receives $40 million upfront and may earn up to…
AstraZeneca agreed to invest $2.0 billion in newly issued Summit Therapeutics convertible preferred equity and to test Summit’s ivonescimab with AstraZeneca antibody-drug conjugates. The initial collaboration pairs ivonescimab, a PD-1/VEGF bispecific originally engineered by…
First-line trastuzumab deruxtecan extended blinded-review median progression-free survival to 14.3 from 8.3 months versus pembrolizumab plus platinum-pemetrexed in the randomized Phase III DESTINY-Lung04 trial. Response rate was 70.0% versus 44.5%. The result establishes a…
FDA granted accelerated approval to Etcamah (camizestrant) with continued CDK4/6 inhibition for adults with HR-positive, HER2-negative advanced breast cancer whose tumors develop an ESR1 mutation in circulating tumor DNA before radiographic progression on first-line…
AstraZeneca and Amgen reported that the 368-patient Phase III CROSSING trial of tezepelumab in eosinophilic esophagitis met both co-primary endpoints at Week 24: histologic remission and improvement in dysphagia. Both tested doses also met…
AstraZeneca disclosed three divergent Phase III lung-cancer outcomes on the same day. In SAFFRON, osimertinib plus savolitinib met progression-free-survival and overall-survival endpoints versus platinum chemotherapy after osimertinib progression in biomarker-selected EGFR-mutant, MET-driven non-small cell…
The European Commission approved AstraZeneca’s Etcamah, or camizestrant, with a CDK4/6 inhibitor for adults with ER-positive, HER2-negative advanced breast cancer when an ESR1 mutation emerges during first-line aromatase-inhibitor plus CDK4/6 therapy but before disease…
AstraZeneca has entered an exclusive global license agreement with China-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral, irreversible EGFR inhibitor for non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The agreement carries…
